APA

Wakuda K., Yamaguchi H., Kenmotsu H., Fukuda M., Takeshita M., Suetsugu T., Kirita K., Ebi N., Hataji O., Miura S., Chibana K., Okamoto I., Yoshimura K., Nakagawa K., Yamamoto N. & Sugio K. (20210122). A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L). : BMC cancer.

Chicago

Wakuda Kazushige, Yamaguchi Hiroyuki, Kenmotsu Hirotsugu, Fukuda Minoru, Takeshita Masafumi, Suetsugu Takayuki, Kirita Keisuke, Ebi Noriyuki, Hataji Osamu, Miura Satoru, Chibana Kenji, Okamoto Isamu, Yoshimura Kenichi, Nakagawa Kazuhiko, Yamamoto Nobuyuki and Sugio Kenji. 20210122. A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L). : BMC cancer.

Harvard

Wakuda K., Yamaguchi H., Kenmotsu H., Fukuda M., Takeshita M., Suetsugu T., Kirita K., Ebi N., Hataji O., Miura S., Chibana K., Okamoto I., Yoshimura K., Nakagawa K., Yamamoto N. and Sugio K. (20210122). A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L). : BMC cancer.

MLA

Wakuda Kazushige, Yamaguchi Hiroyuki, Kenmotsu Hirotsugu, Fukuda Minoru, Takeshita Masafumi, Suetsugu Takayuki, Kirita Keisuke, Ebi Noriyuki, Hataji Osamu, Miura Satoru, Chibana Kenji, Okamoto Isamu, Yoshimura Kenichi, Nakagawa Kazuhiko, Yamamoto Nobuyuki and Sugio Kenji. A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L). : BMC cancer. 20210122.